JAK2 and acute lymphoblastic leukemia: As described below, multiple clinical trials are currently investigating whether addition of the SRC/ABL/PDGFR inhibitor dasatinib or the JAK2 inhibitor ruxolitinib to the backbone of chemotherapy can improve the outcomes of children and adults with Ph-like ALL (13).